A real case in Build Diagnosis
Built in 5 seconds
Input
- Patient
- Female, adult
- CBC
-
- Hgb 11.3 g/dL
- WBC 3.5 K/µL
- Plts 142 K/µL
- MCV 102.7 fL
- ANC 0.86 K/µL
- RDW 14.2%
- Smear
- Few atypical lymphocytes, mild dysgranulopoiesis
- Molecular
- Negative for JAK2 V617F, CALR and MPL. Positive, tier I or II, for ASXL1, TP53 (multi-hit), TET2 and PTPN11.
Output
CBC and smear review reveals mild macrocytic pancytopenia with severe neutropenia, few atypical lymphocytes, mild dysgranulopoiesis and no leukoerythroblastosis, increased teardrop RBCs, basophilia or anisocytosis (Hgb 11.3 g/dL, WBC 3.5 K/µL, Plts 142 K/µL, MCV 102.7 fL, ANC 0.86 K/µL & RDW 14.2%). Molecular study is negative for JAK2 "V617F", CALR and MPL mutations. The multi-hit TP53 mutation confirms a diagnosis of myelodysplastic neoplasm with biallelic TP53 inactivation (MDS-biTP53). PTPN11 and TP53 multi-hit mutations portend adverse prognosis in myeloid neoplasms (MN). Up to 31% of cases with PTPN11, TP53 multi-hit, ASXL1, and TET2 mutations are observed in leukemic transformation (risk of post-MN AML). Bone marrow examination for further evaluation and risk assessment is recommended, if clinically indicated.
Please review the output in light of your input.
